INCY Incyte Corp.

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor for the treatment of adults; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug that is in Phase III clinical trial for steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase III clinical trial to treat naÃ¯ve chronic GVHD; and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, 8p11 myeloproliferative syndrome, and Tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, the company develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; and Cellenkos, Inc., as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Recent Analyst Ratings for Incyte Corp.

Date	Price Target	Rating	Analyst
6/16/2025	$107.00	Hold → Buy	Stifel
3/18/2025		Buy → Neutral	Guggenheim
3/18/2025		Outperform → Mkt Perform	William Blair
12/17/2024	$77.00	Neutral	UBS
10/29/2024	$68.00 → $90.00	Neutral → Buy	BofA Securities
10/1/2024	$84.00	Outperform	Wolfe Research
9/18/2024	$83.00 → $74.00	Buy → Hold	Truist
7/2/2024	$52.00 → $48.00	Market Perform → Underperform	BMO Capital Markets
5/23/2024	$55.00	Hold	Deutsche Bank
4/23/2024		Neutral	Cantor Fitzgerald

See more ratings

Incyte Corp.

Peers

Recent Analyst Ratings for Incyte Corp.

Incyte Corp. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Brawley Otis W was granted 2,518 shares, increasing direct ownership by 29% to 11,252 units (SEC Form 4)

Director Fouse Jacqualyn A was granted 2,518 shares, increasing direct ownership by 15% to 19,326 units (SEC Form 4)

Director Bienaime Jean Jacques was granted 2,518 shares, increasing direct ownership by 14% to 20,841 units (SEC Form 4)

Director Baker Bros. Advisors Lp was granted 5,036 shares (SEC Form 4)

Director High Katherine A was granted 2,518 shares, increasing direct ownership by 23% to 13,341 units (SEC Form 4)

Director Clancy Paul J was granted 2,518 shares, increasing direct ownership by 13% to 22,589 units (SEC Form 4)

Director Schaffert Susanne covered exercise/tax liability with 849 shares and was granted 2,518 shares, increasing direct ownership by 29% to 7,389 units (SEC Form 4)

Director Harrigan Edmund was granted 2,518 shares, increasing direct ownership by 14% to 19,952 units (SEC Form 4)

EVP & General Counsel Denton Sheila A. exercised 1,795 shares at a strike of $58.06 and sold $122,060 worth of shares (1,795 units at $68.00) (SEC Form 4)

Principal Accounting Officer Tray Thomas sold $105,516 worth of shares (1,614 units at $65.38), decreasing direct ownership by 7% to 22,003 units (SEC Form 4)